Clinical Trial Detail

NCT ID NCT02873195
Title Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Academic and Community Cancer Research United
Indications

colorectal cancer

Therapies

Bevacizumab + Capecitabine

Atezolizumab + Bevacizumab + Capecitabine

Age Groups: adult senior

No variant requirements are available.